TABLE II.
Univariate Analysis in Patients with non-Hodgkin’s lymphoma (N = 141)
| N (%) | Poor Mobilizers, N (%) | Odds Ratio | 95% CI | P | |
|---|---|---|---|---|---|
| Platelet count | |||||
| <150 x109/L | 34 | 14 (41) | ref | ||
| ≥150 x109/L | 106 | 12 (11) | 0.2 | 0.1–0.4 | <0.001 |
| Missing | 1 | ||||
| Cellularity | |||||
| <30% | 44 | 13 (30) | 2.7 | 1.1–6.5 | 0.02 |
| ≥30% | 97 | 13 (13) | ref | ||
| Regimen | |||||
| Ifosfamide/etoposide ± Rituximab | 96 | 12 (13) | ref | ||
| G-CSF | 13 | 8 (62) | 11.2 | 3.1–40 | <0.001 |
| Cyclophosphamide ± Rituximab | 14 | 3 (21) | 1.9 | 0.5–7.8 | 0.4 |
| Other | 18 | 3 (17) | 1.4 | 0.3–5.6 | 0.6 |
G-CSF, granulocyte-colony stimulating factor.